{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:25:42Z","timestamp":1791685542397,"version":"4.3.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40265-021-01541-x","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T11:02:32Z","timestamp":1623495752000},"page":"1221-1226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Fuzuloparib: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,12]]},"reference":[{"key":"1541_CR1","unstructured":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. China\u2019s first original PARP inhibitor fluzoparib approved for marketing [media release]. 17 Dec 2020. https:\/\/www.hrs.com.cn."},{"key":"1541_CR2","unstructured":"National Medical Products Administration. Drug Evaluation Center. The National Medical Products Administration approves the marketing of fluzoparib capsules [media release]. 14 Dec 2020. https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/yaopin\/ypjgdt\/20201214100312149.html."},{"key":"1541_CR3","unstructured":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. AiRuiYi\u00ae (fluzoparib) capsules: Chinese prescribing information [Chinese]. Lianyungang: Jiangsu Hengrui Pharmaceuticals Co., Ltd.; 2020."},{"issue":"3","key":"1541_CR4","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/cas.13947","volume":"110","author":"L Wang","year":"2019","unstructured":"Wang L, Yang C, Xie C, et al. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci. 2019;110(3):1064\u201375.","journal-title":"Cancer Sci"},{"key":"1541_CR5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3546","author":"N Li","year":"2021","unstructured":"Li N, Bu H, Liu J, et al. An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian cancer. Clin Cancer Res. 2021. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3546.","journal-title":"Clin Cancer Res"},{"key":"1541_CR6","doi-asserted-by":"crossref","unstructured":"Li N, Zhang Y, Zhu J. Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma: a multicenter, randomized, double-blind, placebo-controlled, phase III trial [abstract no. 11557 plus oral presentation]. In: SGO 2021.","DOI":"10.1016\/S0090-8258(21)00752-6"},{"issue":"3","key":"1541_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.21147\/j.issn.1000-9604.2020.03.08","volume":"32","author":"H Li","year":"2020","unstructured":"Li H, Liu R, Shao B, et al. Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chin J Cancer Res. 2020;32(3):370\u201382.","journal-title":"Chin J Cancer Res"},{"key":"1541_CR8","doi-asserted-by":"crossref","unstructured":"Xu JM, Liu R, Ba Y, et al. Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma [abstract no. 4060]. J Clin Oncol. 2019;37(Suppl. 15):4060.","DOI":"10.1200\/JCO.2019.37.15_suppl.4060"}],"updated-by":[{"DOI":"10.1007\/s40265-021-01570-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000}},{"DOI":"10.1007\/s40265-021-01585-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01541-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01541-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01541-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T13:32:14Z","timestamp":1633008734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01541-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,12]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01541-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,12]]},"assertion":[{"value":"12 June 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01570-6","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01570-6","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01585-z","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01585-z","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}